BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 23163626)

  • 21. [Expression of B cell-specific activator protein in lymphomas].
    Li D; Li GD; Liu WP; Li FY; Zhang WY; Liao DY
    Zhonghua Bing Li Xue Za Zhi; 2005 Jun; 34(6):345-7. PubMed ID: 16185503
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pax8 expression in thymic epithelial neoplasms: an immunohistochemical analysis.
    Weissferdt A; Moran CA
    Am J Surg Pathol; 2011 Sep; 35(9):1305-10. PubMed ID: 21836478
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Value of PAX 8 immunostaining in tumor diagnosis: a review and update.
    Ordóñez NG
    Adv Anat Pathol; 2012 May; 19(3):140-51. PubMed ID: 22498579
    [TBL] [Abstract][Full Text] [Related]  

  • 24. PAX-5: a valuable immunohistochemical marker in the differential diagnosis of lymphoid neoplasms.
    Desouki MM; Post GR; Cherry D; Lazarchick J
    Clin Med Res; 2010 Jul; 8(2):84-8. PubMed ID: 20660931
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Biphenotypic bigenotypic lymphoma with simultaneous expression of PAX5/BSAP and B- and T-cell markers.
    Hansson M; Jerkeman M; Dictor M
    Eur J Haematol; 2007 Aug; 79(2):159-65. PubMed ID: 17635241
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Expression of immunoglobulin transcription factors in primary intraocular lymphoma and primary central nervous system lymphoma.
    Coupland SE; Loddenkemper C; Smith JR; Braziel RM; Charlotte F; Anagnostopoulos I; Stein H
    Invest Ophthalmol Vis Sci; 2005 Nov; 46(11):3957-64. PubMed ID: 16249468
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Expression and significance of B-cell-specific activator protein of H/RS cell in classical Hodgkin's Lymphoma].
    Zhou X; Zhao T; Qi Z; Liu G; Zhu M
    Zhonghua Yi Xue Za Zhi; 2002 Nov; 82(22):1532-5. PubMed ID: 12609061
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Diagnostic utility of PAX2 and PAX5 in distinguishing non-small cell lung cancer from small cell lung cancer.
    Ren Y; Hou J; Xu A; Pan Y
    Int J Clin Exp Pathol; 2015; 8(11):14709-16. PubMed ID: 26823795
    [TBL] [Abstract][Full Text] [Related]  

  • 29. PAX5 expression in rhabdomyosarcoma.
    Morgenstern DA; Gibson S; Sebire NJ; Anderson J
    Am J Surg Pathol; 2009 Oct; 33(10):1575-7. PubMed ID: 19641453
    [No Abstract]   [Full Text] [Related]  

  • 30. Differential patterns of PAX8, p16, and ER immunostains in mesonephric lesions and adenocarcinomas of the cervix.
    Goyal A; Yang B
    Int J Gynecol Pathol; 2014 Nov; 33(6):613-9. PubMed ID: 25272301
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Expression of B cell-specific activator protein/PAX5 in acute myeloid leukemia with t(8;21)(q22;q22).
    Valbuena JR; Medeiros LJ; Rassidakis GZ; Hao S; Wu CD; Chen L; Lin P
    Am J Clin Pathol; 2006 Aug; 126(2):235-40. PubMed ID: 16891199
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The Diagnostic Utility of PAX8 for Neuroendocrine Tumors: An Immunohistochemical Reappraisal.
    Liau JY; Tsai JH; Jeng YM; Kuo KT; Huang HY; Liang CW; Yang CY
    Appl Immunohistochem Mol Morphol; 2016 Jan; 24(1):57-63. PubMed ID: 25710581
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pax5 expression in non-Hodgkin's lymphomas and acute leukemias.
    Zhang X; Lin Z; Kim I
    J Korean Med Sci; 2003 Dec; 18(6):804-8. PubMed ID: 14676435
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Expression profiling of transcription factors in B- or T-acute lymphoblastic leukemia/lymphoma and burkitt lymphoma: usefulness of PAX5 immunostaining as pan-Pre-B-cell marker.
    Nasr MR; Rosenthal N; Syrbu S
    Am J Clin Pathol; 2010 Jan; 133(1):41-8. PubMed ID: 20023257
    [TBL] [Abstract][Full Text] [Related]  

  • 35. PAX-8 expression in primary and metastatic Merkel cell carcinoma: an immunohistochemical analysis.
    Sangoi AR; Cassarino DS
    Am J Dermatopathol; 2013 Jun; 35(4):448-51. PubMed ID: 23612030
    [TBL] [Abstract][Full Text] [Related]  

  • 36. PAX immunoreactivity in poorly differentiated small round cell tumors of childhood.
    Fan R
    Fetal Pediatr Pathol; 2014 Aug; 33(4):244-52. PubMed ID: 24897005
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Use of an expanded immunohistochemical panel to distinguish cutaneous Hodgkin lymphoma from histopathologic imitators.
    Cho RJ; McCalmont TH; Ai WZ; Fox LP; Treseler P; Pincus LB
    J Cutan Pathol; 2012 Jun; 39(6):651-8. PubMed ID: 22324490
    [TBL] [Abstract][Full Text] [Related]  

  • 38. PAX5 expression in acute leukemias: higher B-lineage specificity than CD79a and selective association with t(8;21)-acute myelogenous leukemia.
    Tiacci E; Pileri S; Orleth A; Pacini R; Tabarrini A; Frenguelli F; Liso A; Diverio D; Lo-Coco F; Falini B
    Cancer Res; 2004 Oct; 64(20):7399-404. PubMed ID: 15492262
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The B-cell transcription factors BSAP, Oct-2, and BOB.1 and the pan-B-cell markers CD20, CD22, and CD79a are useful in the differential diagnosis of classic Hodgkin lymphoma.
    Browne P; Petrosyan K; Hernandez A; Chan JA
    Am J Clin Pathol; 2003 Nov; 120(5):767-77. PubMed ID: 14608905
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Multiple isoforms of PAX5 are expressed in both lymphomas and normal B-cells.
    Arseneau JR; Laflamme M; Lewis SM; Maïcas E; Ouellette RJ
    Br J Haematol; 2009 Nov; 147(3):328-38. PubMed ID: 19725825
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.